4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$5.73 USD
-0.32 (-5.29%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $5.66 -0.07 (-1.22%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FDMT 5.73 -0.32(-5.29%)
Will FDMT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FDMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FDMT
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
FDMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
Other News for FDMT
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference | FDMT ...
12 Health Care Stocks Moving In Monday's Intraday Session
FDMT Stock: Analyst Chardan Capital Maintains Buy Rating at $25 | FDMT Stock News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket